Treatment of Primary Ovarian Lymphoma in Anaplastic Lymphoma Kinase-Negative Anaplastic Large-Cell Lymphoma

Clinical Setting

The patient has anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma (ALK-negative ALCL). The absence of ALK expression defines this subtype and shapes the treatment strategy from the outset. First-line treatment of ALK-negative ALCL establishes the baseline from which subsequent management decisions — including how to address relapsed or refractory disease — are derived.

Treatment Approach

In the relapsed or refractory setting, multiple systemic options are recognised within evidence-based guidelines for ALK-negative ALCL. The approach draws on salvage regimens with differing mechanisms, and for patients who are transplant-eligible, consolidation with stem-cell transplantation may be considered as part of the overall strategy.

The complete structured protocol — including the full set of recognised regimen options, sequencing guidance, and transplant eligibility criteria — is available via the link below.